In 1953 was created Edmond de Rothschild Private Equity, which is appeared as VC. The leading representative office of defined VC is situated in the Paris. The company was established in Europe in France.
We also calculated 6 valuable employees in our database.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Edmond de Rothschild Private Equity, startups are often financed by Index Ventures, MP Healthcare Venture Management, Andera Partners. The meaningful sponsors for the fund in investment in the same round are Andera Partners, Index Ventures, Forbion Capital Partners. In the next rounds fund is usually obtained by Nicholas Benedict, Forbion Capital Partners, EMBL Ventures.
Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2013. The fund is constantly included in less than 2 investment rounds annually. Comparing to the other companies, this Edmond de Rothschild Private Equity performs on 54 percentage points more the average number of lead investments. The top amount of exits for fund were in 2014.
Among the various public portfolio startups of the fund, we may underline Genkyotex, Covagen, Allecra Therapeutics For fund there is no match between the location of its establishment and the land of its numerous investments - Switzerland. We can highlight the next thriving fund investment areas, such as Children, Biotechnology. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
Related Funds
Funds with similar focus
Fund Name | Location |
Clean Energy Trust | Chicago, Illinois, United States |
Cloquet Capital Partners | Connecticut, New York, United States |
Decima Ventures | New York, New York, United States |
FEBE Ventures | Central Region, Singapore, Singapore |
Kuka Group | China, Hangzhou, Zhejiang |
MobilityFund | Germany, Hamburg |
Resolve Growth Partners | Baltimore, Maryland, United States |
Shanghai Ruizhe | China, Shanghai |
Toro Ventures | Mexico, Nuevo León, Nuevo Leon |
ZoomInfo | Massachusetts, United States, Waltham |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Swiss Summit Capital | $25M | 05 Apr 2019 | London, England, United Kingdom | ||
Avalyn Pharma | $62M | 01 Jan 2017 | Seattle, Washington, United States | ||
Allecra Therapeutics | $25M | 15 Jun 2016 | Baden-Württemberg | ||
Covagen | $64M | 09 Dec 2013 | Zurich, Switzerland | ||
OncoEthix | $19M | 07 Aug 2013 | Lausanne, Vaud, Switzerland | ||
Allecra Therapeutics | $17M | 18 Apr 2013 | Baden-Württemberg | ||
GlycoVaxyn | $20M | 05 Mar 2009 | Zurich, Switzerland | ||
PanGenetics | $27M | 05 Mar 2008 | Utrecht, Utrecht, Netherlands |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Swiss Summit Capital | $25M | 05 Apr 2019 | London, England, United Kingdom | ||
Avalyn Pharma | $62M | 01 Jan 2017 | Seattle, Washington, United States | ||
Allecra Therapeutics | $25M | 15 Jun 2016 | Baden-Württemberg | ||
Covagen | $64M | 09 Dec 2013 | Zurich, Switzerland | ||
OncoEthix | $19M | 07 Aug 2013 | Lausanne, Vaud, Switzerland | ||
Allecra Therapeutics | $17M | 18 Apr 2013 | Baden-Württemberg | ||
GlycoVaxyn | $20M | 05 Mar 2009 | Zurich, Switzerland | ||
PanGenetics | $27M | 05 Mar 2008 | Utrecht, Utrecht, Netherlands |